In:
Oncology, S. Karger AG, Vol. 70, No. 4 ( 2006), p. 306-314
Abstract:
〈 i 〉 Objective: 〈 /i 〉 It was the aim of this study to evaluate the safety of the optimized cryptic peptide TERT 〈 sub 〉 572Y 〈 /sub 〉 in pretreated patients with advanced cancer. 〈 i 〉 Methods: 〈 /i 〉 Nineteen patients with progressive and chemotherapy-refractory tumors received escalated doses (2–6 mg) of 2 subcutaneous injections of the optimized TERT 〈 sub 〉 572Y 〈 /sub 〉 peptide followed by 4 subcutaneous injections of the native TERT 〈 sub 〉 572 〈 /sub 〉 peptide every 3 weeks. Both TERT peptides were coinjected with adjuvant Montanide ISA51. Toxicity was evaluated every 3 weeks and peptide-specific CD8+ cells were detected by flow cytometry using TERT 〈 sub 〉 572Y 〈 /sub 〉 tetramers. 〈 i 〉 Results: 〈 /i 〉 Fourteen out of 19 patients completed the vaccination program. No grade III/IV toxicity was observed. Grade I anemia was observed in 4 patients and local skin reaction at the injection site in 11 patients. Other nonhematologic toxicities were mild, and no late toxicity was observed after a median postvaccination follow-up period of 10.7 months. There was no dose-limiting toxicity. Peripheral blood TERT 〈 sub 〉 572Y 〈 /sub 〉 -specific CD8+ lymphocytes were detected in 13 out of 14 evaluable patients after 2 injections with the optimized TERT 〈 sub 〉 572Y 〈 /sub 〉 peptide. There was no complete or partial response, but 4 patients (21%) with persistent TERT 〈 sub 〉 572Y 〈 /sub 〉 -specific CD8+ experienced stable disease for a median of 10.5 months. 〈 i 〉 Conclusion: 〈 /i 〉 TERT 〈 sub 〉 572Y 〈 /sub 〉 peptide vaccine is well tolerated and effective in eliciting specific TERT 〈 sub 〉 572Y 〈 /sub 〉 CD8+ lymphocytes in pretreated cancer patients, demonstrating that cryptic peptides could be used in cancer immunotherapy.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2006
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Bookmarklink